Volume 23, Number 5—May 2017
Research
Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection
Table 1
Serostatus, serum sample ID |
Place of Infection |
IC50† |
||||
DENV-1 |
DENV-2 |
DENV-3 |
DENV-4 |
Zika virus |
||
Primary DENV-1 | ||||||
147 | Latin America | 3,552 | 287 | 557 | 75 | <20 |
153 | Latin America | 757 | <20 | <20 | <20 | <20 |
05/262 | Asia | 274 | <20 | <20 | <20 | <20 |
06/125 | Asia | 3,823 | 222 | 125 | 80 | <20 |
99/1230 |
Asia |
1,219 |
63 |
30 |
24 |
<20 |
Primary DENV-2 | ||||||
001 | Asia | 49 | 2,188 | 48 | 89 | <20 |
08/90 | Asia | <20 | 2,966 | <20 | <20 | <20 |
08/91 | Asia | <20 | 838 | <20 | <20 | <20 |
09/165 | Asia | <20 | 2,093 | <20 | <20 | <20 |
09/251 |
Asia |
<20 |
417 |
<20 |
<20 |
<20 |
Primary DENV-3 | ||||||
116 | Asia | 200 | 979 | 5,342 | 290 | <20 |
118 | Latin America | 173 | 374 | 3,041 | 56 | <20 |
125 | Latin America | 99 | 97 | 1,648 | 35 | <20 |
133 | Latin America | 89 | 171 | 3,348 | 83 | <20 |
06/297 |
Asia |
27 |
<20 |
573 |
<20 |
<20 |
Primary DENV-4 | ||||||
112 | Latin America | 908 | 1367 | 591 | 18,408 | <20 |
06/105 | Asia | <20 | <20 | <20 | 941 | <20 |
06/302 | Asia | <20 | <20 | <20 | 4,130 | <20 |
09/159 |
Asia |
115 |
226 |
478 |
5,694 |
<20 |
Primary Zika virus | ||||||
168 | Latin America | 36ǂ | <20 | 78‡ | <20 | 1,382 |
172 |
Latin America |
<20 |
<20 |
<20 |
<20 |
8,468 |
Secondary DENV | ||||||
000 | Asia | 3,306 | 2,087 | 1,162 | 782 | <20 |
003 | Asia | 556 | 178 | 299 | <20 | 146 |
115 | Asia | 100 | 355 | 830 | 245 | <20 |
141 | Latin America | 1,902 | 1,953 | 4,530 | 664 | <20 |
144 | Asia | 155 | 191 | 5,782 | 1,612 | 699 |
145 | Asia | 601 | 1,262 | 240 | 60 | <20 |
146 | Asia | 403 | 1,052 | 1,480 | 451 | 28 |
155 | Asia | 215 | 299 | 71 | 27 | <20 |
160 | Latin America | 947 | 3,564 | 131 | 1,600 | <20 |
06/123 | Asia | 1,776 | 827 | 82 | 157 | <20 |
06/124 | Asia | 1,454 | 1,208 | 1,673 | 1,011 | <20 |
09/157 | Asia | 282 | 1,104 | 73 | 134 | <20 |
09/250 |
Asia |
375 |
1475 |
151 |
94 |
<20 |
Secondary Zika virus | ||||||
165 | Latin America | 60‡ | 79‡ | 70‡ | 508 | 1655 |
166 | Latin America | 929 | 393 | 4344 | 240 | 1814 |
*DENV, dengue virus; IC50, 50% inhibitory concentration; ID, identification.
†All neutralization testing performed on Vero cells with the exception of DT003, which was limiting and historic values performed on a U937 Flow-based assay are shown for DENV-1–4. Zika virus IC50 values for DT003 are from Vero assays.
‡Curves that did not pass quality metrics are marked. Such curves might signify very low titer IC50 values or variable background at the lower limit of detection in serum with no specific neutralization activity.
Page created: April 14, 2017
Page updated: April 14, 2017
Page reviewed: April 14, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.